These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11773299)

  • 61. Taxanes in elderly breast cancer patients.
    Wildiers H; Paridaens R
    Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
    Cristofanilli M; Gonzalez-Angulo AM; Buzdar AU; Kau SW; Frye DK; Hortobagyi GN
    Clin Breast Cancer; 2004 Feb; 4(6):415-9. PubMed ID: 15023242
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
    Nowak AK; Wilcken NR; Stockler MR; Hamilton A; Ghersi D
    Lancet Oncol; 2004 Jun; 5(6):372-80. PubMed ID: 15172358
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Impact of taxanes in the adjuvant setting of node-negative breast cancers].
    Lagha A; Chraiet N; Labidi S; Krimi S; Ayadi M; Gligorov J; Boussen H
    Bull Cancer; 2013 May; 100(5):465-71. PubMed ID: 23613145
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Development of docetaxel in the adjuvant chemotherapy of breast cancer].
    Fattoruso SI; Rossi S; Di Lauro L; Botti C; Vici P; Lopez M
    Clin Ter; 2008; 159(5):369-76. PubMed ID: 18998039
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Taxane containing regimens for metastatic breast cancer.
    Ghersi D; Wilcken N; Simes J; Donoghue E
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003366. PubMed ID: 15846659
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
    Gogas H; Fountzilas G
    Ann Oncol; 2003 May; 14(5):667-74. PubMed ID: 12702519
    [No Abstract]   [Full Text] [Related]  

  • 73. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of taxanes in adjuvant therapy.
    Münster PN; Hudis CA
    Cancer Invest; 2000; 18(1):32-8. PubMed ID: 10701365
    [No Abstract]   [Full Text] [Related]  

  • 75. Combined anthracycline-taxane regimens in the adjuvant setting.
    Mamounas EP; Sledge GW
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):24-31. PubMed ID: 11552227
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New chemotherapeutic agents for breast cancer.
    Abrams JS; Moore TD; Friedman M
    Cancer; 1994 Aug; 74(3 Suppl):1164-76. PubMed ID: 7913662
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
    Tsavaris N; Kosmas C; Vadiaka M; Kanelopoulos P; Boulamatsis D
    Br J Cancer; 2002 Jul; 87(1):21-7. PubMed ID: 12085250
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adjuvant taxanes: more to the story.
    Gajria D; Seidman A; Dang C
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S41-9. PubMed ID: 20805064
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].
    Fattoruso SI; Rossi S; Vici P; Di Filippo F; Botti C; Di Lauro L; Foggi P; Saracca E; Ferranti FR; Visca P; Lopez M
    Clin Ter; 2008; 159(6):443-7. PubMed ID: 19169606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.